Free Trial

MTU Aero Engines 2/29/2024 Earnings Report

Bone Biologics logo
$0.70 +0.01 (+1.56%)
Closing price 04/11/2025 03:58 PM Eastern
Extended Trading
$0.71 +0.01 (+1.72%)
As of 04/11/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bone Biologics EPS Results

Actual EPS
$1.54
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bone Biologics Revenue Results

Actual Revenue
$1.84 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bone Biologics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bone Biologics' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Conference Call Resources

Remove Ads

Bone Biologics Earnings Headlines

BBLG Continues Crucial Testing
DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
See More Bone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bone Biologics and other key companies, straight to your email.

About Bone Biologics

Bone Biologics (NASDAQ:BBLG), a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

View Bone Biologics Profile

More Earnings Resources from MarketBeat